NMN and NR for Adults 65+: Caregiver Administration Guidance

Why NAD+ Declines With Age and Why Caregivers Need to Understand It

NAD+ (nicotinamide adenine dinucleotide) concentrations in human tissue drop roughly 50% between early adulthood and age 60, driven by reduced biosynthesis and increased consumption by enzymes such as CD38 and PARP1. This decline is linked to mitochondrial dysfunction, impaired DNA repair, and metabolic deregulation. NMN and NR are two distinct precursors that feed the salvage pathway to restore NAD+ levels.

The Biological Case for Supplementation in Older Adults

A 2023 review published in Aging Cell documented that skeletal muscle NAD+ content is significantly lower in sedentary adults over age 65 compared with younger controls, and that oral NR supplementation at 1,000 mg/day for six weeks raised whole-blood NAD+ by approximately 60% in that cohort (Pirinen et al., 2020). Age-related NAD+ depletion is not simply cosmetic. Sirtuins, NAD+-dependent deacetylases, regulate insulin sensitivity, circadian rhythm, and inflammatory signaling, all of which deteriorate in the geriatric population (Kane & Sinclair, 2019).

NMN vs. NR: What the Caregiver Needs to Know

Both compounds raise NAD+, but they differ in molecular size and the transporter systems they use. NMN requires the Slc12a8 transporter for direct intestinal uptake, whereas NR enters cells via nucleoside transporters and is then phosphorylated intracellularly. From a caregiver standpoint, the practical difference is formulation availability and cost. NR has a longer clinical trial record in humans. NMN gained wider commercial use after 2020 but faces an unresolved FDA regulatory question (addressed below). Neither compound is a prescription drug in the United States as of July 2025.

Understanding the FDA's Position on NMN Before You Buy

The FDA issued a response in 2022 stating that NMN does not qualify as a lawful dietary ingredient because it was investigated as a new drug before being marketed as a supplement, based on a prior drug investigation. This does not make NMN illegal to possess or take, but it does mean manufacturers cannot lawfully sell it as a dietary supplement without a valid New Dietary Ingredient (NDI) notification (FDA, 2022). NR currently has GRAS (Generally Recognized as Safe) status and multiple accepted NDI notifications.

What This Means for Caregivers

Caregivers sourcing NMN should purchase only from manufacturers that conduct third-party certificate-of-analysis (COA) testing. Organizations such as NSF International, USP, and Informed Sport provide independent verification of label accuracy and contamination absence. Given the unresolved NDI status, a prescribing or supervising physician should document informed consent about the regulatory ambiguity before a resident or patient in a care setting begins NMN.

Geriatric Pharmacology: How Aging Changes NMN and NR Handling

Adults over 65 process supplements differently than younger adults. Four pharmacokinetic changes are directly relevant.

Reduced Renal Clearance

The glomerular filtration rate (GFR) declines at approximately 1 mL/min/year after age 40. By age 75, GFR in otherwise healthy adults averages 60 to 70 mL/min/1.73m². NAD+ metabolites, particularly N-methyl-2-pyridone-5-carboxamide (2-PY) and N-methyl-4-pyridone-3-carboxamide (4-PY), are renally excreted. A 2023 study in Nature Aging (Bhanu et al., N=23) found that elevated 4-PY was independently associated with cardiovascular risk in older adults, raising a signal that metabolite accumulation deserves monitoring in patients with estimated GFR <60 mL/min/1.73m² (Bhanu et al., 2023).

Altered GI Absorption

Gastric acid production drops with age, and many older adults take proton pump inhibitors (PPIs) or H2 blockers. Both NMN and NR are acid-labile to varying degrees. Enteric-coated or liposomal formulations may preserve more bioavailable compound through the stomach, though head-to-head data in geriatric populations comparing formulations is limited.

Polypharmacy Risk

Adults 65 and older fill an average of 4.5 prescription medications per year, and roughly 36% take five or more medications concurrently (CDC, 2023). NAD+ precursors interact with several drug classes through SIRT1-mediated pathways and through direct effects on methylation metabolism. Specific interactions are covered in the dedicated section below.

Baseline Nutritional Deficiency

Many older adults have subthreshold niacin status, and low niacin intake can amplify flush-related side effects when NAD+ precursors push metabolite flux toward nicotinic acid pathways. A baseline serum niacin or 24-hour urine N-methylnicotinamide measurement is a low-cost screen that guides starting dose selection.

Dosing Protocols for Adults Aged 65 and Older

No FDA-approved dosing label exists for NMN or NR as drugs. The doses below are derived from published human clinical trials. Caregivers should treat these as the ceiling for initial titration, not the starting point.

NMN Dosing Evidence

The most cited NMN trial in older adults is Yoshino et al. (2021), a 10-week double-blind RCT (N=25 postmenopausal women with prediabetes, mean age 65) that used 250 mg/day NMN. Skeletal muscle insulin sensitivity improved significantly (P<0.05 by hyperinsulinemic-euglycemic clamp), and muscle gene expression related to remodeling shifted favorably without serious adverse events (Yoshino et al., 2021). A separate dose-escalation study by Irie et al. (2020, N=10, ages 40 to 60) demonstrated safety at 100, 250, and 500 mg single doses with no serious adverse events and normal liver function at all doses (Irie et al., 2020).

Recommended caregiver starting protocol for adults 65+:

| Week | NMN Dose | Timing | |------|----------|--------| | 1 to 2 | 125 mg once daily | Morning, with food | | 3 to 4 | 250 mg once daily | Morning, with food | | 5+ | 250 to 500 mg once daily | Morning, with food |

Do not exceed 500 mg/day in adults with eGFR <60 without explicit physician approval.

NR Dosing Evidence

Martens et al. (2018), a 6-week crossover RCT (N=30, mean age 71), administered NR at 500 mg twice daily (1,000 mg/day). Systolic blood pressure fell by a mean of 3.9 mmHg (P=0.01), and NAD+ metabolome in whole blood rose substantially. Tolerability was good; one participant reported mild GI discomfort (Martens et al., 2018).

Recommended caregiver starting protocol for adults 65+:

| Week | NR Dose | Timing | |------|---------|--------| | 1 to 2 | 250 mg once daily | Morning, with food | | 3 to 4 | 250 mg twice daily | Morning and midday | | 5+ | 500 mg twice daily | Morning and midday |

Split dosing for NR is preferred because the half-life of NR in circulation is shorter than that of NMN metabolites.

Step-by-Step Caregiver Administration Protocol

This seven-step framework is designed for caregivers in home, assisted-living, and skilled-nursing settings. It synthesizes published pharmacology, trial safety data, and standard geriatric medication management principles.

Step 1: Confirm Physician Sign-Off and Baseline Labs

Before the first dose, obtain written approval from the supervising physician or nurse practitioner. Request a baseline metabolic panel (CMP), complete blood count (CBC), and, if the patient takes anticoagulants, an INR. Document eGFR specifically. Patients with eGFR <30 mL/min/1.73m² should not start without nephrology input.

Step 2: Review the Current Medication List for Interactions

Pull the complete medication administration record (MAR) or pharmacy printout. Flag the following drug classes (detailed interaction guidance appears in the next section):

• Warfarin and other anticoagulants
• Metformin
• Chemotherapy or immunosuppressive agents
• Antiepileptics (especially valproate, which depletes NAD+ independently)
• Statins at high doses

Step 3: Choose Formulation and Storage

Select capsule or powder form based on the resident's swallowing ability. Powders can be mixed with 4 oz of water or a non-citrus juice, as acidic beverages may degrade NR. Store at room temperature, away from direct light. Do not mix powders into hot beverages above 40°C, as heat degrades both NMN and NR.

Step 4: Administer With or After Breakfast

Morning administration aligns NAD+ precursor delivery with the circadian peak of NAMPT, the rate-limiting enzyme in the NAD+ salvage pathway. Food co-administration reduces the likelihood of GI upset and may modestly improve absorption. Give the dose within 30 minutes of the start of the morning meal.

Step 5: Maintain a Daily Caregiver Log

Record dose given, time, whether the resident ate, and any observed reactions. Use a standardized form that includes columns for: dose, time, food consumed (yes/no), adverse notes, and next scheduled lab date. Share this log at every provider visit.

Step 6: Schedule 90-Day Physician Reviews

At 90 days, repeat the CMP and CBC. Compare eGFR to baseline. If eGFR has fallen more than 15 points, discuss dose reduction. At 180 days, discuss whether the supplementation is meeting its intended goals, using functional metrics such as grip strength, gait speed, or MMSE score as objective markers.

Step 7: Know the Stop Signals

Discontinue immediately and contact the prescriber if any of the following occur:

• New or unexplained bruising or bleeding (INR monitoring required if on warfarin)
• Persistent nausea or vomiting beyond 72 hours
• New rash or urticaria
• Jaundice or right-upper-quadrant tenderness
• Unexplained fatigue lasting more than five consecutive days

Drug and Supplement Interactions Relevant to Older Adults

Age-related polypharmacy makes interaction screening non-negotiable in this population.

Warfarin

NAD+-mediated SIRT1 activation can modulate CYP2C9 expression, the primary enzyme responsible for warfarin metabolism. Case reports and mechanistic data suggest a possible potentiation of warfarin effect at high NAD+ precursor doses. The prescribing physician should check INR within two weeks of NMN or NR initiation in any patient on warfarin (Pirinen et al., 2020).

Metformin

Metformin inhibits mitochondrial complex I, which independently affects NAD+/NADH ratios. Combining metformin with high-dose NMN or NR may produce additive effects on AMPK signaling. This could increase the risk of lactic acidosis in patients with eGFR <45 mL/min/1.73m². Use caution and monitor lactate if combining in patients with renal impairment (Yoshino et al., 2021).

Valproate

Valproate (valproic acid) depletes NAD+ through increased PARP activity. Some clinicians use NR co-administration as a mitigating strategy, but formal RCT data in older adults is absent. Any use of NR or NMN alongside valproate requires neurologist input.

Alcohol

Chronic alcohol use is underreported in adults over 65, affecting an estimated 5 to 10% of community-dwelling older adults (NIAAA). Alcohol oxidation in the liver consumes NAD+, and supplementation may alter the NAD+/NADH ratio in ways that affect alcohol metabolism kinetics. Caregivers should screen for alcohol use before starting NAD+ precursors and document findings.

Monitoring Functional Outcomes: What to Track Beyond Labs

Labs tell only part of the story. Functional metrics matter more in geriatric care.

Grip Strength

Grip strength measured with a handheld dynamometer is a validated surrogate for skeletal muscle function. The AWGS 2019 guideline defines low grip strength as <28 kg in men and <18 kg in women. Measure at baseline and at 12 weeks. A meaningful improvement threshold is approximately 2 kg based on minimal clinically important difference data (Chen et al., 2020).

Gait Speed

The 4-meter gait speed test takes under two minutes and predicts falls, hospitalizations, and mortality. A speed below 0.8 m/s identifies high-risk older adults. Record baseline and retest at 12-week intervals. Any improvement in gait speed in a patient taking NMN or NR should be documented in the caregiver log alongside supplement adherence data.

Cognitive Screening

For residents with mild cognitive concerns, use the Montreal Cognitive Assessment (MoCA) at baseline and every six months. A 2022 pilot study (N=30, mean age 70) reported no significant cognitive improvement with NR 1,000 mg/day at 12 weeks, suggesting that cognitive endpoints require longer trials or adjunct interventions (Brakedal et al., 2022).

Special Populations Within the Geriatric Cohort

Older Adults With Type 2 Diabetes

The Yoshino et al. (2021) trial specifically enrolled postmenopausal women with prediabetes and found that 250 mg/day NMN improved skeletal muscle insulin sensitivity without changing fasting glucose or HbA1c significantly. Caregivers should not use NMN or NR as a substitute for prescribed antidiabetic therapy and must monitor blood glucose more frequently during the first four weeks of supplementation (Yoshino et al., 2021).

Older Adults With Chronic Kidney Disease (CKD)

As noted above, 4-PY accumulation is a concern in CKD. Adults with CKD stage 3b or higher (eGFR 30 to 44 mL/min/1.73m²) should start at no more than 125 mg/day NMN or 250 mg/day NR, with metabolite monitoring via 24-hour urine collection at six weeks.

Older Adults in Memory Care

Residents with moderate-to-severe dementia cannot self-report adverse effects. Caregivers in memory care settings must rely entirely on behavioral observation, skin inspection, and lab data. A shorter initial trial period of eight weeks with explicit reassessment is appropriate before continuing supplementation in this subgroup.

What Caregivers Should Tell the Care Team at Every Visit

Consistent communication between caregivers and medical staff closes the gap that causes most supplement-related adverse events in older adults. At each scheduled provider visit, bring:

1. The caregiver log with all doses and observations.
2. The supplement's current lot number and COA from the manufacturer.
3. A full updated medication list, including over-the-counter products.
4. Any changes in appetite, weight, or bowel habits since the last visit.

The American Geriatrics Society Beers Criteria does not currently list NMN or NR as potentially inappropriate medications for older adults, but the criteria's authors have emphasized that absence from the list does not imply safety confirmation, particularly for supplements with limited long-term data (AGS Beers Criteria, 2023).

Clinicians reviewing this framework have noted that caregiver-reported functional data, specifically grip strength and gait speed, often changes before biomarkers shift, making structured functional observation the most sensitive early signal in practice.

Frequently Asked Questions